Structure-based rescue of common tumor-derived p53 mutants

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1143-1146

  Wieczorek, Ania M ^a   Waterman, Jennifer L F ^a   Waterman, Matthew J F ^a,b   Halazonetis, Thanos D ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL DEATH; DNA DAMAGE; DNA REPAIR; MUTANT; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLOSTERIC SITE; BASE SEQUENCE; BINDING SITES; DNA; GENES, P53; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0029823529     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1143     Document Type: Article

References (20)

1. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
2. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
3. Ko, L.J. & Prives, C. p53: Puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
4. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49-53 (1991).
5. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355 (1994).
6. Friend, S. p53: A glimpse at the puppet behind the shadow play. Science 265, 334-335 (1994).
7. Halazonetis, T.D., Davis L.J. & Kandil, A.N. Wild-type p53 adopts a "mutant"-like conformation when bound to DNA. EMBO J. 12, 1021-1028 (1993).
8. Hupp, T.R., Meek, D.W., Midgley, C.A. & Lane, D.P. Regulation of the specific DNA binding function of p53. Cell 71, 875-886 (1992).
9. Waterman, J.L.F., Shenk, J.L. & Halazonetis, T.D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14, 512-519 (1995).
10. Halazonetis, T.D. & Kandil, A.N. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12, 5057-5064 (1993).
11. Hupp, T.R., Meek, D.W., Midgley, C.A. & Lane, D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21, 3167-3174 (1993).
12. Niewolik, D., Vojtesek, B. & Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10, 881-890 (1995).
13. Finlay, C.A. et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8, 531-539 (1988).
14. El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
15. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
16. Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830 (1992).
17. Finlay, C.A., Hinds, P.W. & Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093 (1989).
18. Waterman, M.J.F., Waterman, J.L.F. & Halazonetis, T.D. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res. 56, 158-163 (1996).
19. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
20. Graeber, T.G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).